PURPOSE: Most studies examining accelerated partial breast irradiation (APBI) have used twice-daily fractionation. Cosmesis with this approach has produced mixed results, and the optimal fractionation scheme remains unknown. We sought to evaluate the safety and efficacy of APBI with a total dose of 40 Gy in 10 daily fractions. METHODS AND MATERIALS: Between 2010 and 2014, we prospectively enrolled 106 patients to receive APBI after lumpectomy for invasive or in situ node-negative breast cancer. Radiation was administered via 3-dimensional conformal techniques. RESULTS: The median age was 62 years (range, 39-85), and all patients underwent APBI per protocol. With a median follow-up of 58 months, we evaluated patient-reported local toxicity and recurrence outcomes. Of 106 patients, 16 (15%) experienced grade ≥2 skin toxicity. The most common significant toxicities were acute cutaneous changes at 4 to 9 weeks after radiation therapy, including grade 2 erythema in 2 patients (1.8%) and skin color changes in 4 patients (3.8%). Only 2 instances of grade 3 toxicity were reported, including 1 patient with acute moist desquamation after radiation therapy and another with fibrosis at 2 years. Planning target volume and breast V20 were significantly predictive of skin/subcutaneous toxicity, with evidence that limiting breast V20 to <45% may improve tolerability. Overall, 3 breast cancer recurrences arose: 1 local recurrence in the original quadrant (3 years after APBI), 1 in a different ipsilateral quadrant (5 years after APBI), and 1 with distant disease 2 years after APBI. CONCLUSIONS: In an appropriately selected group of patients with early stage breast cancer, APBI to a dose of 40 Gy in 10 daily fractions was well tolerated, with most patients (99%) reporting excellent/good cosmesis. Planning target volume and breast V20 should be carefully constrained to limit local morbidity. Longer follow-up will be needed to establish efficacy and subsequent local recurrence rates.
PURPOSE: Most studies examining accelerated partial breast irradiation (APBI) have used twice-daily fractionation. Cosmesis with this approach has produced mixed results, and the optimal fractionation scheme remains unknown. We sought to evaluate the safety and efficacy of APBI with a total dose of 40 Gy in 10 daily fractions. METHODS AND MATERIALS: Between 2010 and 2014, we prospectively enrolled 106 patients to receive APBI after lumpectomy for invasive or in situ node-negative breast cancer. Radiation was administered via 3-dimensional conformal techniques. RESULTS: The median age was 62 years (range, 39-85), and all patients underwent APBI per protocol. With a median follow-up of 58 months, we evaluated patient-reported local toxicity and recurrence outcomes. Of 106 patients, 16 (15%) experienced grade ≥2 skin toxicity. The most common significant toxicities were acute cutaneous changes at 4 to 9 weeks after radiation therapy, including grade 2 erythema in 2 patients (1.8%) and skin color changes in 4 patients (3.8%). Only 2 instances of grade 3 toxicity were reported, including 1 patient with acute moist desquamation after radiation therapy and another with fibrosis at 2 years. Planning target volume and breast V20 were significantly predictive of skin/subcutaneous toxicity, with evidence that limiting breast V20 to <45% may improve tolerability. Overall, 3 breast cancer recurrences arose: 1 local recurrence in the original quadrant (3 years after APBI), 1 in a different ipsilateral quadrant (5 years after APBI), and 1 with distant disease 2 years after APBI. CONCLUSIONS: In an appropriately selected group of patients with early stage breast cancer, APBI to a dose of 40 Gy in 10 daily fractions was well tolerated, with most patients (99%) reporting excellent/good cosmesis. Planning target volume and breast V20 should be carefully constrained to limit local morbidity. Longer follow-up will be needed to establish efficacy and subsequent local recurrence rates.
Authors: S J Schnitt; J L Connolly; U Khettry; G Mazoujian; M Brenner; B Silver; A Recht; G Beadle; J R Harris Journal: Cancer Date: 1987-02-15 Impact factor: 6.860
Authors: R Holland; J L Connolly; R Gelman; M Mravunac; J H Hendriks; A L Verbeek; S J Schnitt; B Silver; J Boyages; J R Harris Journal: J Clin Oncol Date: 1990-01 Impact factor: 44.544
Authors: Sofie De Langhe; Thomas Mulliez; Liv Veldeman; Vincent Remouchamps; Annick van Greveling; Monique Gilsoul; Eline De Schepper; Kim De Ruyck; Wilfried De Neve; Hubert Thierens Journal: BMC Cancer Date: 2014-09-25 Impact factor: 4.430
Authors: Grazia Lazzari; Angela Terlizzi; Giuseppina Della Vittoria Scarpati; Francesco Perri; Vincenzo De Chiara; Barbara Turi; Giovanni Silvano Journal: Onco Targets Ther Date: 2017-03-24 Impact factor: 4.147
Authors: P McGale; C Taylor; C Correa; D Cutter; F Duane; M Ewertz; R Gray; G Mannu; R Peto; T Whelan; Y Wang; Z Wang; S Darby Journal: Lancet Date: 2014-03-19 Impact factor: 79.321
Authors: J Isabelle Choi; Kiran Prabhu; William F Hartsell; Todd DeWees; Christopher Sinesi; Carlos Vargas; Rashmi K Benda; Oren Cahlon; Andrew L Chang Journal: Clin Transl Radiat Oncol Date: 2022-08-28
Authors: Lior Z Braunstein; Erin F Gillespie; Linda Hong; Amy Xu; Samuel F Bakhoum; John Cuaron; Boris Mueller; Beryl McCormick; Oren Cahlon; Simon Powell; Atif J Khan Journal: Adv Radiat Oncol Date: 2020-04-01